Shares of FibroGen Inc. (NASDAQ:FGEN) rose 3% during mid-day trading on Monday . The stock traded as high as $19.15 and last traded at $18.96, with a volume of 202,756 shares. The stock had previously closed at $18.41.

FGEN has been the topic of several recent research reports. Credit Suisse Group AG reissued a “buy” rating and issued a $38.00 price target on shares of FibroGen in a report on Tuesday, May 10th. Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a report on Tuesday, May 10th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $33.25.

The firm’s 50 day moving average is $18.30 and its 200 day moving average is $18.32. The firm’s market cap is $1.23 billion.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by $0.01. On average, analysts expect that FibroGen Inc. will post ($1.26) earnings per share for the current fiscal year.

In related news, insider K Peony Yu sold 2,344 shares of the business’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $17.96, for a total transaction of $42,098.24. Following the transaction, the insider now directly owns 210,257 shares in the company, valued at $3,776,215.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas B. Neff sold 37,798 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $18.38, for a total value of $694,727.24. Following the transaction, the chief executive officer now owns 3,413,255 shares in the company, valued at $62,735,626.90. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in FibroGen stock. Rhumbline Advisers boosted its stake in shares of FibroGen Inc. (NASDAQ:FGEN) by 8.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,940 shares of the biopharmaceutical company’s stock after buying an additional 3,675 shares during the period. Rhumbline Advisers owned about 0.07% of FibroGen worth $1,400,000 at the end of the most recent reporting period.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.